Status:
COMPLETED
Prevalence of BRCA in Patients With Ovarian Cancer
Lead Sponsor:
AGO Research GmbH
Conditions:
BRCA Status
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The aim of this prospective registration and translational research study is to evaluate the praevalence of BRCA regarding germline and somatic mutations.
Detailed Description
Explorative analysis will be performed.
Eligibility Criteria
Inclusion
- Female ovarian cancer patients aged \>= 18 years.
- Women with first diagnosis of epithelial ovarian cancer OR women diagnosed with platinum-sensitive recurrent ovarian cancer.
- Multiple platinum based prior therapies are allowed.
Exclusion
- Non-epithelial ovarian malignancy.
- Platinum-resistant or refractory disease.
- Paraffin embedded tumor samples not available.
Key Trial Info
Start Date :
March 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
530 Patients enrolled
Trial Details
Trial ID
NCT02222883
Start Date
March 1 2015
End Date
April 1 2021
Last Update
June 16 2021
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité - Universitätsmedizin Berlin
Berlin, Germany
2
Universitätsklinik Carl Gustav Carus
Dresden, Germany
3
Evangelisches Krankenhaus
Düsseldorf, Germany
4
Kliniken Essen-Mitte
Essen, Germany